undamentalytics Newsletter
Sign in

Puma Biotechnology, Inc. income statement

In fiscal 2025, Puma Biotechnology, Inc. reported revenue of $228m, down 0.9% on the year before, operating income of $37.3m (a 16.3% margin) and net income of $31.1m, or $0.61 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue28251272225253228236230228231
Cost of revenue6353739645563645858
Gross profit22216235186189173173166170173
Research and development20816513398725250556271
Selling, general and administrative1071461421181169090807171
Operating income−292−95−39−3012433313730
Interest expense11115141312131274
Income before tax—−114−76−60−29023243631
Income tax0000001−65—
Net income−292−114−76−60−29022303127
Diluted EPS−$7.85−$2.99−$1.95−$1.52−$0.72$0.00$0.45$0.62$0.61$0.52
Diluted shares (average)37m38m39m40m41m45m48m49m51m52m
EBITDA−290−87−31−20133444424838

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IDYA vs PBYIANAB vs PBYIPBYI vs RYTMAKBA vs PBYI

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Puma Biotechnology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Puma Biotechnology, Inc.